Abstract
Objective: The study is aimed to evaluate the antiparkinsonian effect of polyherbal formulation containing methanolic extract of Prunus amygdalus, Arachis hypogaea, and Citrullus lanatus (MEPAC) in chlorpromazine (CPZ)-induced Parkinson’s disease in Wistar albino rats.
 Methods: The antiparkinsonian activity of polyherbal formulation was studied in CPZ (3 mg/kg i.p.) induced Parkinson rat model. Rats were subjected to treatment with MEPAC and standard drug for a period of 21 days. The behavioral assessments, i.e., catalepsy and locomotor activity were assessed during the treatment period. Then animals were sacrificed, brains were isolated and homogenized for the estimation of biochemical parameters such as dopamine (DA), lipid peroxidation (LPO), glutathione (GSH), and superoxide dismutase (SOD). Histopathology of the brains was also done.
 Results: The cataleptic score of MEPAC (200 mg/kg and 400 mg/kg) treated rats was significantly reduced. On the other hand, there was improved in the locomotor activity. MEPAC (200 mg/kg and 400 mg/kg) treated rats showed increase in the level of DA, reduced GSH, SOD, and decreased LPO significantly.
 Conclusion: It may be concluded that methanolic extract of polyherbal formulation consisting of P. amygdalus, A. hypogaea, and C. lanatus showed a good antioxidant and neuroprotective effect in CPZ-induced Parkinson rats.
Highlights
Neurodegenerative diseases (NDDs) are defined as debilitating disorders that cause progressive neuronal loss in the brain which results in impaired mental functioning and difficulty in movement
Effect of MEPAC on CPZ-induced catalepsy in rats screened by wooden block The cataleptic score of the experimental rats was investigated on days 1, 7, 14, and 21 of the experimental duration
Administration of CPZ (3 mg/kg, ip) induced catalepsy significantly and the cataleptic score was significantly higher in disease control group when compared to the control group
Summary
Neurodegenerative diseases (NDDs) are defined as debilitating disorders that cause progressive neuronal loss in the brain which results in impaired mental functioning and difficulty in movement. The incidence and prevalence of PD increases along with increasing age and affects 1% of people over the age of 65 years [3]. It is a movement disorder of the central nervous system which occurs due to the loss of dopamine (DA) producing cells in the brain. This loss transpires in substantia nigra pars compacta of midbrain which depletes the DA in the striatum. The present treatments for NDDs are limited to providing symptomatic relief to disease but do not alleviate damage to the neurons [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
